---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268046"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:01:50.675135+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neumora Q3 net loss $56.8M; cash $171.5M; pipeline updates on NMRA-215, M4 PAMs, NMRA-511

## Summary
- Net loss of $56.8M for Q3 2025 vs $72.5M in Q3 2024; R&D expense down to $40.5M from $60.6M.
- Cash, equivalents, and marketable securities $171.5M; expects to fund operations into 2027.
- Drew $40M non-dilutive capital from K2 HealthVentures facility.
- NMRA-215 (NLRP3 inhibitor) showed class-leading weight loss in DIO mouse models; Phase 1 expected Q1 2026.
- NMRA-511 Phase 1b data in Alzheimer's agitation expected around year-end; navacaprant KOASTAL topline in 1H 2026.

## SEC filing metadata
- accession: 0001193125-25-268046
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/0001193125-25-268046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268046
- JSON: https://secwatch.observer/filing/0001193125-25-268046.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.